WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
IFN.USPT.	3539
IFNS.USPT.	343
INTERFERON.USPT.	11042
INTERFERONS.USPT.	4553
COMBINATION.USPT.	1102104
COMBINATIONS.USPT.	337789
COMBINED.USPT.	687489
COMBINEDS.USPT.	1
COMPOSITION.USPT.	568895
COMPSN.USPT.	203
COMPSNS.USPT.	43
((IFN OR INTERFERON) SAME (COMBINATION OR COMBINED) SAME (COMPOSITION) SAME (ANTIBIOTIC) SAME (CHEMOTHERAPEUTIC)).USPT.	20

There are more results than shown above. Click here to view the entire set.

Database:
- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search: L5

Refine Search

Recall Text | Clear

Search History

DATE: Thursday, October 10, 2002 Printable Copy Create Case

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
IFN.USPT.	3539
IFNS.USPT.	343
INTERFERON.USPT.	11042
INTERFERONS.USPT.	4553
COMBINATION.USPT.	1102104
COMBINATIONS.USPT.	337789
COMBINED.USPT.	687489
COMBINEDS.USPT.	1
COMPOSITION.USPT.	568895
COMPSN.USPT.	203
COMPSNS.USPT.	43
((IFN OR INTERFERON) SAME (COMBINATION OR COMBINED) SAME (COMPOSITION) SAME (ANTIBIOTIC) SAME (CHEMOTHERAPEUTIC)).USPT.	20

There are more results than shown above. Click here to view the entire set.

Database:
- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search: L5

Refine Search

Recall Text | Clear

Search History

DATE: Thursday, October 10, 2002 Printable Copy Create Case

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
GAMMA.USPT.	127188
GAMMAS.USPT.	551
(3 SAME GAMMA).USPT.	23
(L3 SAME GAMMA).USPT.	23

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L4

Refine Search | Recall Text | Clear

Search History

DATE: Thursday, October 10, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L4	L3 same gamma	23	L4
L3	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or chemotherapeutic)	134	L3
L2	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or antifungal or chemotherapeutic)	136	L2
L1	(ifn or interferon) same (combination or combined) same (composition) same (cancer or tumor or tumour or chemotherapeutic)	234	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
GAMMA.USPT.	127188
GAMMAS.USPT.	551
(3 SAME GAMMA).USPT.	23
(L3 SAME GAMMA).USPT.	23

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L4

Refine Search | Recall Text | Clear

Search History

DATE: Thursday, October 10, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=ADJ		
L4	L3 same gamma	23	L4
L3	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or chemotherapeutic)	134	L3
L2	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or antifungal or chemotherapeutic)	136	L2
L1	(ifn or interferon) same (combination or combined) same (composition) same (cancer or tumor or tumour or chemotherapeutic)	234	L1

END OF SEARCH HISTORY

C12-L04
ABEQ US 5019382 A UPAB: 19930923
In an improved method of treating infectious disease of viral origin in human, canine and feline species, about 0.01 to about 5 IU, pref. 0.1-4.0 IU of interferon per lb of body wt. per dose, is contacted with the oral and pharyngeal mucosa of the species.
Pref. the interferon is alpha- or beta-interferon, esp. alpha-interferon produced from human leukocytes.
Pref. the treated viral infection is human rhinovirus, herpes, simplex I virus, herpes simplex II virus, viral myocarditis or HILV III virus (AIDS).
ADVANTAGE - Remission is effected of neoplastic disease, hyperallergenicity, immuno-resistant viral infections etc..
ABEQ EP 341258 B UPAB: 19940418
A composition comprising interferon and a pharmaceutically acceptable carrier therefore, in an effervescent tablet form adapted for dissolution in water to form a mouthwash or gargle formulation for human patient use for stimulating an immunotherapeutic response in said patient, said effervescent tablets containing 1 to 1500 IU of interferon.
Dwg.0/0

L119 ANSWER 27 OF 31 WPIX (C) 2002 THOMSON DERWENT
AN 1987-251462 [36] WPIX
DNC C1987-106397
TI Synergistic antiviral compsn. contg. **interferon** at **low dose** - plus tumour necrosis factor or lymphotoxin, esp. for treating and preventing aids.
DC B04 C03
IN WONG, G H; WONG, G H W
PA (GETH) GENENTECH INC
CYC 23
PI EP 235906 A 19870909 (198736)* EN 27p
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
AU 8767962 A 19870730 (198737)
JP 62215535 A 19870922 (198743)
DK 8700371 A 19870725 (198746)
GB 2194146 A 19880302 (198809)
HU 43957 T 19880128 (198810)
PT 84869 A 19880729 (198835)
ZA 8700470 A 19880722 (198844)
CN 87100480 A 19871111 (198846)
DD 263234 A 19881228 (198922)
US 4828830 A 19890509 (198922) 13p
EP 235906 B 19900926 (199039)
R: AT BE CH DE ES FR GB GR IT LI LU NL SE
DE 3765137 G 19901031 (199045)
CA 1296252 C 19920225 (199214)
ES 2031882 T3 19930101 (199305) A61K037-66
DK 169234 B 19940919 (199436) A61K037-66
JP 2510181 B2 19960626 (199630) 17p A61K038-21 <--
ADT EP 235906 A EP 1987-300589 19870123; JP 62215535 A JP 1987-15030 19870123; GB 2194146 A GB 1987-11424 19870514; ZA 8700470 A ZA 1987-470 19870122; ES 2031882 T3 EP 1987-300589 19870123; DK 169234 B DK 1987-371 19870123; JP 2510181 B2 JP 1987-15030 19870123
FDT ES 2031882 T3 Based on EP 235906; DK 169234 B Previous Publ. DK 8700371; JP 2510181 B2 Previous Publ. JP 62215535
PRAI US 1986-892531 19860731; US 1986-822099 19860124
REP DE 3227262; EP 128009; EP 131789; EP 170843; WO 8603751
IC ICM A61K037-66; **A61K038-21**
ICS A61K009-12; A61K037-02; A61K038-00; A61K038-44; A61K039-42; A61K045-02; C12N007-00
ICI A61K037-66, A61K037:
AB EP 235906 A UPAB: 19970502

WO 1986-US2783 19861222, EP 1987-902456 19861222; CA 1323564 C CA 1987-545085 19870821
FDT EP 253887 B1 Based on WO 8704076; DE 3688841 G Based on EP 253887, Based on WO 8704076
PRAI US 1985-814317 19851230
REP FR 2537436; FR 2575655; WO 8200588; 5.Jnl.Ref; 10Jnl.Ref
IC A61K039-26; A61K045-02
ICM A61K037-66; A61K039-39
ICS A61K039-26; A61K039-265; A61K045-02
AB WO 8704076 A UPAB: 19931116
Efficiency of a vaccine in warm-blooded vertebrates is enhanced by admin. in conjunction with admin. of a vaccine contg. a biologically active interferon (I) in a dosage up to 5 IU/lb body wt.

(I) is pref. adminstered at 1 IU/lb daily. It is suitably human interferon-alpha. The first vaccine pref. is of the type used to confer protection against bovine respiratory disease complex in cattle. It may contain infectious bovine rhinotracheitis (IBR) virus, other viruses, bacteria, mycoplasma, chlamyolia, etc. With IBR vaccine, dosages of 10 to the power 5.5-6.0 TCD 50/ml are normally used. With (I) the dosage should allow redn. of the dosage by a factor of 10 to 100.

USE/ADVANTAGE - When (I) is used, the amount of filled or attenuated micro-organisms needed to give an effective vaccination dose can be reduced, so that the chances of detrimental vaccine infection are reduced. The vaccine may also obtd. more economically. There may also be a quicker antibody response. (I) is pref. administered orally, but parentral, intranasal and other routes may be used. Admin. may be simultaneously with the first vaccine or up to one day before or after. For simultaneous admin., the two vaccines may be combined or used separately. (I) has been used in antiviral and antitumour therapy and as an immunomodulatory agent.
Dwg.0/0
FS CPI
FA AB
MC CPI: B02-V02; **B02-V03**; B12-A01; B12-A06; B12-D02B; B12-G07;
C02-V02; **C02-V03**; C12-A01; C12-A06; C12-D02B; C12-G07
ABEQ US 4820514 A UPAB: 19930922
A method of enhancing efficiency of vaccine comprises of co-admin. less than 5 (pref. 1.0) IU/lb of interferon p.o. Interferon may be homo- or hetero-logous for animals, pref. human alpha interferon for humans.

ADVANTAGE - Reduces amt of vaccine required by 10-100 fold and is of economic importance in prevention or treatment of cattle BRDC.
ABEQ EP 253887 B UPAB: 19931118
A combination for vaccinating a warm-blooded vertebrate, including: a vaccine for inducing immunity to an infectious disease; and at least one dose of a biologically active interferon in a dosage form for oral administration in an amount no greater than 5 IU of interferon/lb (11 IU/kg) of body weight of said vertebrate per unit dose; in which combination the vaccine and the dose of interferon are optionally in a form for independent administration.
Dwg.0/0

L119 ANSWER 29 OF 31 WPIX (C) 2002 THOMSON DERWENT
AN 1986-340015 [52] WPIX
CR 1986-101073 [16]; 1986-101574 [16]; 1986-126252 [20]; 1986-132434 [21]; 1987-023031 [04]
DNC C1986-147364
TI **Gamma-interferon low dosage** use -
for treatment of auto immune diseases, virus infections and malignant diseases.
DC B04
IN BRZOSKA, J; EICHBORN, J F; OBERT, H J
PA (BIOF-N) BIOFERON BIOCHEM SU
CYC 1
PI DE 3608608 A 19861218 (198652)* 24p

ADT DE 3608608 A DE 1986-3608608 19860314
PRAI EP 1985-112625 19851004; EP 1985-107490 19850618; EP 1985-111184 19850904
IC A61K045-02
AB DE 3608608 A UPAB: 19971113
Use of **gamma-interferon (IFN-gamma**) in a daily dosage (based on adult patients of ca 60kg bodyweight and 1.7 metres body surface) of 0.1-2 million internation reference units (IU) or ca 10-200 microgrammes at daily to monthly intervals for the systemic treatment of autoimmune diseases, virus diseases and malignant diseases of humans is new.
USE/ADVANTAGE - **Low dosages** of **IFN-gamma** are effective against autoimmune diseases (e.g. multiple sclerosis, amylotrophic lateral sclerosis, Crohn's disease, asthma, allergies, psoriasis and non-rheumatic pains), viral diseases and malignant diseases. Higher doses are less effective.
Dwg.0/0
FS CPI
FA AB
MC CPI: **B02-V03**; **B12-A06**; **B12-A07**; B12-C10; B12-D01; **B12-D02**; **B12-D07**; B12-E02; **B12-G07**; **B12-K02**

L119 ANSWER 30 OF 31 WPIX (C) 2002 THOMSON DERWENT
AN 1986-218778 [34] WPIX
CR 1984-153736 [25]
DNC C1986-094317
TI **Low dosage interferon** administration to warm blooded vertebrates - to increase food utilisation efficiency and treat various bovine conditions.
DC B04 C03
IN **CUMMINS, J M**
PA (TEXA) UNIV TEXAS A & M SYSTEM
CYC 7
PI AU 8551630 A 19860710 (198634)* 43p
FR 2575655 A 19860711 (198634)
DE 3600083 A 19860918 (198639)
BR 8600071 A 19860923 (198645)
ZA 8509894 A 19861021 (198704)
US 4820515 A 19890411 (198917)
IT 1207573 B 19890525 (199133)
DE 3645343 A1 19960321 (199617) A23K001-16
DE 3600083 C2 19960725 (199634) 20p A61K038-21 <--
DE 3645343 C2 19971120 (199750) 18p A23K001-16
US 5910304 A 19990608 (199930) A61K038-21 <--
ADT AU 8551630 A AU 1985-51630 19851224; FR 2575655 A FR 1986-46 19860103; DE 3600083 A DE 1986-3600083 19860103; ZA 8509894 A ZA 1985-9894 19851230; US 4820515 A US 1985-688868 19850104; DE 3645343 A1 Div ex DE 1986-3600083 19860103, DE 1986-3645343 19860103; DE 3600083 C2 DE 1986-3600083 19860103; DE 3645343 C2 Div ex DE 1986-3600083 19860103, DE 1986-3645343 19860103; US 5910304 A CIP of US 1982-448951 19821213, Cont of US 1985-688868 19850104, Cont of US 1987-44317 19870430, US 1992-875630 19920428
FDT DE 3645343 A1 Div ex DE 3600083; DE 3600083 C2 Div in DE 3645343; DE 3645343 C2 Div ex DE 3600083; US 5910304 A CIP of US 4497795, Cont of US 4820515
PRAI US 1985-688868 19850104; US 1982-448951 19821213; US 1987-44317 19870430; US 1992-875630 19920428
IC A23K001-16; A23L000-00; A61K045-02
ICM A23K001-16; **A61K038-21**
ICS A23K001-165; A23L000-00; A61K045-02
AB AU 8551630 A UPAB: 19960503
A biologically active **interferon** is administered to warm-blooded

vertebrates in a daily dosage of at most about 5 IU/lb body wt. Cpd. is pref. of human **interferon** alpha, orally at a daily dosage of 0.1-1.5 IU/lb. for 3 consecutive days. The administration can be to bovine, porcine, caprine, ovine, avian feline, canine and equine animals, as well as humans.

USE/ADVANTAGE - The administration may be for (i) increasing the efficiency of food utilisation; (ii) preventing and treating bovine respiratory disease; (iii) treating a ship-stressed cow; or (iv) preventing and treating infectious bovine rhino tracheitis. The dosages are much smaller than those previously used.

0/0

Dwg.0/0

FS CPI

FA AB

MC CPI: **B02-V03; B12-K06;** B12-L09; **C02-V03; C12-K06;** C12-L09

ABEQ US 4820515 A UPAB: 19930922

Increasing the appetite and efficiency of food utilisation in warm-blooded vertebrates comprises admin. (pref. oral) of a biologically active **interferon** (pref. human **interferon** alpha) in a dosage not greater than 5 IU (pref. 0.1-1.5 IU or 3 consecutive days) per lb. of body wt. per day.

ADVANTAGE - Much lower doses can be used than were previously.

L119 ANSWER 31 OF 31 WPIX (C) 2002 THOMSON DERWENT

AN 1986-101574 [16] WPIX

CR 1986-101073 [16]; 1986-126252 [20]; 1986-132434 [21]; 1986-340015 [52]; 1987-023031 [04]

DNC C1986-043441

TI Systemic treatment of human disease with **low doses** of **gamma interferon** - e.g. for control of tumours, virus disease, psoriasis and allergy.

DC B04

IN EICHBORN, J; LINK, F; OBERT, H; BRZOSKA, J; EICHBORN, J F; OBERT, H J; VON, EICHBORN J

PA (BIOF-N) BIOFERON BIOCHEM SU; (BIOF-N) BIOFERON BIOCHEM SUBSTANZ; (RENT) RENTSCHLER BIOTECHNOLOGIE GMBH; (BIOF-N) BIOFERON BIOCHEM; (BIOF-N) BIOFERON BICHEMISCHE SUBSTANZEN GMBH

CYC 18

PI

EP 177910	A	19860416 (198616)* DE	22p			
R: AT BE CH DE FR GB IT LI LU NL SE						
DE 3436638	A	19860417 (198617)				
AU 8548408	A	19860410 (198622)				
AU 8548412	A	19860410 (198622)				
JP 61091135	A	19860509 (198625)				
JP 61093130	A	19860512 (198625)				
DK 8504524	A	19860406 (198627)				
DE 3436638	C	19860814 (198633)				
ZA 8507721	A	19860731 (198644)				
DE 3521733	A	19861218 (198652)				
DE 3546568	A	19870723 (198730)				
DE 3572441	G	19890928 (198940)				
DE 3521733	C	19910411 (199115)				
IL 76591	A	19910610 (199130)				
DE 3583849	G	19910926 (199140)				
CA 1288694	C	19910910 (199141)				
DE 3448450	A	19920423 (199218)				
DE 3448460	A	19920730 (199232)			A61K037-66	
US 5145677	A	19920908 (199239)		8p	A61K037-66	
JP 05044930	B	19930707 (199330)		6p	A61K037-66	
JP 2662214	B2	19971008 (199745)		6p	A61K038-21	<--
JP 10087506	A	19980407 (199824)		8p	A61K038-21	<--
JP 11255665	A	19990921 (199950)		8p	A61K038-21	<--

ADT DE 3436638 A DE 1984-3436638 19841005; JP 61091135 A JP 1985-188689 19850829; JP 61093130 A JP 1985-218143 19851002; DE 3436638 C DE 1985-3521733 19850618; ZA 8507721 A ZA 1985-7721 19851007; DE 3521733 A DE 1985-3546568 19850618; DE 3448450 A DE 1984-3448450 19841005; DE 3448460 A Div ex DE 1984-3436638 19841005, DE 1984-3448460 19841005; US 5145677 A Cont of US 1985-784419 19851004, US 1990-510714 19900418; JP 05044930 B JP 1985-188689 19850829; JP 2662214 B2 JP 1985-218143 19851002; JP 10087506 A Div ex JP 1985-218143 19851002, JP 1997-61337 19851002; JP 11255665 A Div ex JP 1997-61337 19851002, JP 1998-339113 19851002

FDT DE 3448450 A Div ex DE 3436638; DE 3448460 A Div ex DE 3436638; JP 05044930 B Based on JP 61091135; JP 2662214 B2 Previous Publ. JP 61093130

PRAI DE 1985-3521733 19850618; DE 1984-3436637 19841005; DE 1984-3436638 19841005; DE 1984-3448450 19841005; DE 1984-3448460 19841005; EP 1985-107490 19850618

REP No-SR.Pub

IC ICM A61K037-66; **A61K038-21**
ICS A61K009-08; A61K031-00; A61K031-70; A61K035-14; A61K045-02; C07K015-00

ICA C12N015-09; C12P021-02

AB EP 177910 A UPAB: 19991201
The use of **gamma interferon** (I) contg. compsns. for systemic treatment of human diseases is new. The daily dose is 0.1-2 million IU (10-200 microg) for a patient of 60 kg body wt. and 1.7 sq.m. body surface area, and the treatment is administered at daily to monthly intervals.

USE - The method is specified for: treatment of tumours (solid tumours or malignant haematological systemic diseases); recidivist prophylaxis of tumours; treatment and prophylaxis of acute or chronic virus diseases; treatment of diseases, esp. condylomata acuminata, caused by human papilloma virus; and treatment of psoriasis, allergies (esp. bronchial asthma), Crohn disease, amylotrophic lateral sclerosis, multiple sclerosis and pain.

Dwg.0/0

FS CPI

FA AB

MC CPI: **B02-V03**; **B12-A06**; **B12-A07**; B12-C10; B12-D01; **B12-D02**; B12-E02; **B12-G07**; B12-J01; **B12-K02**

ABEQ DE 3436638 C UPAB: 19930922
Pharmaceutical compsn. for the treatment of rheumatic illnesses comprises **gamma-interferon** and opt. other **interferons** and/or active prods. generated by leucocytes, dispersed with the usual carriers and opt. additives. These prepns. contain 1 ng- 10 mg **gamma-interferon**, and are suitable for intravenous, intramuscular, subcutaneous, intracutaneous, intra-articular or intrathecal administration.

USE - The prods. are valuable therapeutics, esp. for the treatment of inflammatory, degenerative and extra-articular rheumatism or chronic polyarthritis.

ABEQ DE 3521733 C UPAB: 19930922
Use of **interferon-gamma** prepns. is claimed to treat amyotropic lateral sclerosis. The prepns. contains 20,000-2,000,000 international reference units (IE) per doses, corresp. to 2-200 micro g **interferon**. The prepn. opt. contains other **interferons** and/or cell mediators fromed form leukocytes, produced e.g. by gene technology. The prepns. are used for intravenous, intramuscular or subcutaneous application, or as nasal- or inhalation-sprays or sublingual tablets.

USE/ADVANTAGE - Amyotropic lateral sclerosis is a disease due to degeneration of neurons of the CNS concerned with voluntary movement. It may opt. be caused by a slow virus.

In an example patient with ALS was treated with 0.1 x 10 power 5 IE **interferon-gamma** increasing to 1 x 10 power 6 IE 3 times

WEST

Generate Collection | Print

L3: Entry 39 of 134 File: USPT Feb 27, 2001

DOCUMENT-IDENTIFIER: US 6193966 B1
TITLE: Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies

Detailed Description Text (66):
The compounds of the invention can be incorporated into pharmaceutical compositions suitable for administration to a subject in vivo. In a preferred embodiment, the pharmaceutical composition comprises either a multispecific molecule (compound, or agent) of the invention and a pharmaceutically acceptable carrier. In yet another embodiment of the present invention, the pharmaceutical composition can be administered by combination therapy, i.e., combined with other agents. For example, the combination therapy can include a composition of the present invention with at least one anti-cancer agent, at least one antibiotic, at least one cytokine, at least one vaccine, or other conventional therapy. Exemplary anti-cancer agents include cis-platin, adriamycin, and taxol. Exemplary antibiotics include isoniazid, rifamycin, and tetracycline. Exemplary cytokines include G-CSF, GM-CSF, interleukins and interferons.

Column 25, line 18-30

600/103

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=ADJ		
L5	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic) same (chemotherapeutic)	20	L5
L4	L3 same gamma	23	L4
L3	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or chemotherapeutic)	134	L3
L2	(ifn or interferon) same (combination or combined) same (composition) same (antibiotic or antifungal or chemotherapeutic)	136	L2
L1	(ifn or interferon) same (combination or combined) same (composition) same (cancer or tumor or tumour or chemotherapeutic)	234	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:38:37 ON 10 OCT 2002)

FILE 'USPATFULL' ENTERED AT 12:38:49 ON 10 OCT 2002
L1 54 S (INTERFERON (W) GAMMA)/CLM AND (PHARMACEUTICAL COMPOSITION)/C
L2 9 S L1 AND (ANTIBIOTIC? OR CHEMOTHER? OR ANTIFUNG? OR ANTIFIBRO?)

=> d bib,kwic 1-9

L2 ANSWER 1 OF 9 USPATFULL
AN 2002:259486 USPATFULL
TI Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
IN Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
Tari, Ana M., Houston, TX, UNITED STATES
Lim, Soo-Jeong, Seoul, KOREA, REPUBLIC OF
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2002143062 A1 20021003
AI US 2001-982113 A1 20011017 (9)
PRAI US 2000-241445P 20001017 (60)
DT Utility
FS APPLICATION
LREP FULBRIGHT & JAWORSKI L.L.P., A REGISTERED LIMITED LIABILITY PARTNERSHIP, Suite 2400, 600 Congress Avenue, Austin, TX, 78701
CLMN Number of Claims: 130
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3985
CLM What is claimed is:
12. The method of claim 11, wherein the anticancer agent is **chemotherapy** agent, a radiotherapy agent, an immune therapy agent, a genetic therapy agent, a hormonal therapy agent, a biological agent, an. . .
44. The **pharmaceutical composition** of claim 43, wherein said dimyristoyl phosphatidylcholine and soybean oil comprise a ratio of greater than 80:20.

45. The **pharmaceutical composition** of claim 43, wherein said composition further comprises at least one additional agent.

46. The **pharmaceutical composition** of claim 45, wherein said agent further comprises a linking moiety attached to said agent and one or more lipids. . .
47. The **pharmaceutical composition** of claim 45, wherein said agent comprises a targeting agent.

48. The **pharmaceutical composition** of claim 47, wherein said targeting agent comprises at least one antibody to a tumor.

49. The **pharmaceutical composition** of claim 45, wherein said agent comprises an additional therapeutic agent.

50. The **pharmaceutical composition** of claim 49, wherein said additional therapeutic agent comprises an anticancer agent.

51. The method of claim 50, wherein the anticancer agent is **chemotherapy** agent, a radiotherapy agent, an immune therapy agent, a genetic therapy agent, a hormonal therapy agent, a biological agent, an. . .
52. The **pharmaceutical composition** of claim 43, wherein said composition is comprised as a lyophylized material.

53. The **pharmaceutical composition** of claim 43, wherein said composition is comprised in a pharmaceutically acceptable

WEST Search History

DATE: Thursday, October 10, 2002

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=OR		
L13	L2 with (pharmaceutical composition).clm	143	L13
L12	L8 same (antibiotic$ or chemother$ or antifung$ or antifibro$).clm	12	L12
L11	L8 same dosa$	4	L11
L10	L8 with (dosa$)	2	L10
L9	L8 with (dosa$ from 10 to 50,000 IU)	5	L9
L8	L2 with (pharmaceutical composition)	143	L8
L7	L2 same (pharmaceutical composition)	349	L7
L6	L5 and (from 10 to 10000IU)	1663	L6
L5	L4 and dosage	1670	L5
L4	L2 and (pharmaceutical composition)	2532	L4
L3	L2 and (pharmaceutical composition).clm	2532	L3
L2	(interferon)adj(gamma).clm	2828	L2
L1	interferon adj gamma.clm	0	L1

END OF SEARCH HISTORY

a week over 4 weeks and 0.5 x 10 power 6 IE once a week for 4 weeks. During therapy, the function of the upper extremities improved, with stretching and bending of the hands and elbows becoming opt.. The shoulders could also be moved slightly.

ABEQ US 5145677 A UPAB: 19930922

Therapeutic compsn. comprises natural and/or recombinant **gamma-interferone** and/or their active derivs. dispersed with the usual carriers and opt. additives. The active dosage is 10-200 micro-g daily.

USE - The prods. are therapeutics for neoplastic diseases, tumours, carcinomas, sarcomas, myelomas, lymphomas, papillomas, malignant haematological systemic diseases, Chrohn's disease, degenerative illnesses, viral diseases, asthma, allergies, psoriasis and painful conditions, etc.

0/0

ABEQ JP 93044930 B UPAB: 19931118

The use of **gamma interferon** (I) contg. compsns. for systemic treatment of human diseases is new. The daily dose is 0.1-2 million IU (10-200 microg) for a patient of 60 kg body wt. and 1.7 sq.m. body surface area, and the treatment is administered at daily to monthly intervals.

USE - The method is specified for treatment of tumours (solid tumours or malignant haematological systemic diseases); recidivist prophylaxis of tumours; treatment and prophylaxis of acute or chronic virus diseases; treatment of diseases, esp. condylomata acuminata, caused by human papilloma virus; and treatment of psoriasis, allergies (esp. bronchial asthma), Crohn's disease, amylotrophic lateral sclerosis, multiple sclerosis and pain. (J61091135-A)

=> d his

(FILE 'HOME' ENTERED AT 10:06:22 ON 20 AUG 2002)
SET COST OFF

FILE 'MEDLINE' ENTERED AT 10:08:54 ON 20 AUG 2002
E INTERFERON/CT
E E76+ALL
E E2+ALL

L1	26801	S	E53+NT
L2	26801	S	E53/CN OR E71/CN
L3	38601	S	(INTERFERON OR IFN)(S)GAMMA
L4	24236	S	(INTERFERON OR IFN)(S)TYPE II
L5	42541	S	L1-L4
L6	32130	S	L5 AND PY<=1999
L7	1967	S	L1 (L) TU./CT
L8	11093	S	L1 (L) PD./CT
L9	789	S	L1 (L) AD./CT
L10	11980	S	L7-L9
L11	1036	S	IFNGAMMA
L12	29	S	GAMMAIFN
L13	512	S	L11,L12 AND PY<=1999
L14	32242	S	L6,L13
L15	10193	S	L14 AND L10
L16	5414	S	L15 AND L1/MAJ
L17	369	S	L16 NOT AB/FA
L18	5045	S	L16 NOT L17
L19	498	S	L9 AND L18
L20	3479	S	L18 NOT INTERFERON-GAMMA, RECOMBINANT/CT,CN
L21	130	S	L9/MAJ AND L20
L22	130	S	L21 AND (DOSE OR DOSAGE)

E DOSE-RESPONSE/CT
E E4+ALL

L23	176912	S	E3+NT

```
L24          20 S L23 AND L22
L25          11 S L24 AND C4./CT
L26           2 S L24 AND (C2. OR C3.)/CT
L27           0 S L24 AND  C1./CT
L28           4 S L24 AND (C5. OR C6. OR C7. OR C8. OR C9. OR C10.)/CT
L29           6 S L24 AND (C11. OR C12. OR C13. OR C14. OR C15. OR C16. OR C17.
L30           4 S L24 AND (C21. OR C22. OR C23.)/CT
L31          20 S L24-L30
L32          10 S L31 AND A11./CT
L33         126 S L22 AND (C1. OR C2. OR C3. OR C4. OR C5. OR C6. OR C7. OR C8.
L34           6 S L33 AND ?INFLAM?
L35          66 S L20 AND LOW DOSE
L36           1 S L20 AND LOW DOSAGE
L37          66 S L35,L36
L38          14 S L37 AND L23
L39           4 S L38 AND C4./CT
L40          30 S L37 AND C4./CT
L41          30 S L39,L40
L42          17 S L41 NOT RECOMBINANT
L43          16 S L42 NOT CLONOGENIC/TI
L44          26 S L32,L43
L45           8 S L31 NOT L44
L46          34 S L44,L45
L47          34 S L46 AND L1-L46
L48         517 S L14 AND ACUTE(S)?INFLAM?
L49        4291 S L14 AND MONOCYT?
L50        1049 S L14 AND NEUTROPHIL
L51        2433 S L14 AND B CELL
L52        1741 S L14 AND B LYMPHOCYTE
L53        6010 S L14 AND C4./CT
L54         579 S L14 AND INFLAMMATION+NT/CT
L55        1434 S L14 AND B-LYMPHOCYTES+NT/CT
L56        2171 S L14 AND MONOCYTES+NT/CT
L57         631 S L14 AND NEUTROPHILS+NT/CT
L58        4138 S L14 AND (C1. OR C3.)/CT
L59        2660 S L14 AND B3./CT
L60         378 S L14 AND B5./CT
L61          37 S L14 AND FIBROSIS+NT/CT
L62        5650 S L14 AND C20./CT
L63       19877 S L48-L62
L64         675 S L63 AND L23
L65         272 S L64 AND L1/MAJ
L66         233 S L65 AND (L7/MAJ OR L8/MAJ OR L9/MAJ)
L67          17 S L66 AND LOW()(DOSE OR DOSAGE)
L68          48 S L47,L67 AND L1-L67
L69          28 S L68 AND A11./CT
L70          48 S L68,L69
L71          19 S L14 AND REPERFUSION INJURY+NT/CT
L72          66 S L71,L70
L73          53 S L1/MAJ AND L72

     FILE 'MEDLINE' ENTERED AT 10:41:13 ON 20 AUG 2002

     FILE 'WPIX' ENTERED AT 10:41:55 ON 20 AUG 2002
L74        1530 S L11 OR L12 OR L3 OR L4
L75          36 S INF(S)GAMMA
L76           2 S INFGAMMA OR GAMMAINF
L77        1539 S L74-L76
L78          70 S C07K014-57/IC,ICM,ICS
L79          19 S C07K014-57/ICA,ICI
L80           0 S C07K014:57/ICI
L81         870 S A61K038-21/IC,ICM,ICS
L82         105 S A61K038-21/ICA,ICI
```

```
L83          18 S A61K038:21/ICI
L84        2298 S L77-L83
L85         183 S (B04-H05C OR C04-H05C)/MC
L86         799 S (B02-V03 OR C02-V03)/MC
L87        2860 S L84-L86
               E R12268+ALL/DCN
L88         196 S E1
L89        2882 S L87,L88
L90          14 S L89 AND (LOZENG? OR PASTIL? OR TROCHE? OR SUCK? OR CONFECTION
L91          10 S L90 AND A61K038/IC,ICM,ICS
L92           4 S L90 NOT L91
L93           8 S L89 AND (AMENTO ? OR CUMMINS ?)/AU
L94          15 S L91,L93
L95        1416 S L89 AND (P220 OR P241 OR P420 OR P431 OR P633 OR P714 OR P820
L96         618 S L89 AND (B14-A01? OR C14-A01? OR B12-A0? OR C12-A0? OR B14-A0
L97         295 S L89 AND (B14-C03 OR C14-C03 OR B12-D07 OR C12-D07)/MC
L98         841 S L89 AND (B14-H01 OR C14-H01 OR B12-G07 OR C12-G07)/MC
L99         213 S L89 AND (B14-K01# OR C14-K01# OR B12-K06 OR C12-K06 OR B12-D0
L100         55 S L89 AND (B14-N01 OR C14-N01 OR B12-J08 OR C12-J08)/MC
L101         11 S L95-L100 AND L94
L102         11 S L101 AND INTERFERON
L103          3 S L102 AND GAMMA
L104         12 S L94,L101,L102 NOT L103
L105          1 S L104 AND GAMMA
L106          4 S L103,L105
L107         11 S L94,L101-L105 NOT L106
L108         31 S L89 AND LOW()(DOSE OR DOSAGE)
L109          5 S L108 AND L94
L110         23 S L108 AND L95-L100
L111         28 S L106,L109,L110
L112          6 S L108 NOT L111
L113          1 S L112 AND ORAL REMEDY
L114         29 S L111,L113
L115         14 S L114 AND (?INTERFERON? OR IFN OR INF)(L)GAMMA
L116         15 S L114 NOT L115
L117         11 S L116 AND INTERFERON
L118         25 S L115,L117
L119         31 S L93,L118

     FILE 'WPIX' ENTERED AT 11:04:06 ON 20 AUG 2002
```